23050-54-6

Δ⁸-THC Acetate (CRM) is a certified reference material that is structurally similar to known phytocannabinoids. Δ⁸-THC is regulated as a Schedule I compound in the United States. Δ⁸-THC Acetate (CRM) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.

Delta8-THC acetate (Delta8-tetrahydrocannabinol) is a psychoactive phytocannabinoid, that binds to cannabinoid receptor 1 (CB1 receptor), and exhibits anti-nausea, appetite-stimulating, and anti-inflammatory activities. Delta8-THC acetate exhibits probably neuroprotective efficacy and can be used in anti-anxiety and antidepressant research[1].

[1] Hayakawa K, et al., Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals (Basel). 2010 Jul 8;3(7):2197-2212. DOI:10.3390/ph3072197